Clinical Trials Logo

Clinical Trial Summary

The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA


Clinical Trial Description

Multicentric, observational, single arm, prospective, study. All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protocol, as follows: - Baseline, before the treatment with Lu-PSMA, CT and WB-MRI will be performed - At the end of treatment with Lu-PSMA, CT and WB-MRI will be performed - In post-treatment follow-up every 4 months, until progression or for 1 year, CT and WB-MRI will be performed. Patients participating in this observational study will not be subjected to any additional procedure that falls outside the clinical practice or the study 185.03 Lu-PSMA trial at IRST. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05208229
Study type Observational
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact Oriana Nanni
Phone +39054373900
Email [email protected]
Status Recruiting
Phase
Start date February 22, 2020
Completion date June 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03480646 - ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT03874884 - 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Recruiting NCT03549000 - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Phase 1
Recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Terminated NCT04052204 - Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03724747 - Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Completed NCT04516161 - EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Withdrawn NCT02130947 - Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide N/A